schliessen

Filtern

 

Bibliotheken

Cover Image

Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy

Respiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here, we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection in infants. We developed a mathematical model for maternal vaccine-induced antibody dynamics and used c... Full description

Journal Title: Vaccine 2018-07-25, Vol.36 (31), p.4693-4700
Main Author: Scheltema, Nienke M
Other Authors: Kavelaars, Xynthia M , Thorburn, Kentigern , Hennus, Marije P , van Woensel, Job B , van der Ent, Cornelis K , Borghans, José A.M , Bont, Louis J , Drylewicz, Julia
Format: Electronic Article Electronic Article
Language: English
Subjects:
Analysis
Antibodies, Viral - blood
Antibody Formation
Children
Development and progression
Female
Gestational age
Hospitalization
Humans
Immunization
Infant
Infant mortality
Infant, Newborn
Infants
Infections
Life-threatening infections
Male
Maternal vaccination
Mathematical model
Mathematical models
Medical research
Medicine, Experimental
Models
Models, Theoretical
Mortality
Netherlands - epidemiology
Patient outcomes
Pregnancy
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - epidemiology
Respiratory Syncytial Virus Infections - mortality
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus Vaccines - administration & dosage
Respiratory Syncytial Virus Vaccines - immunology
RSV
Survival Analysis
United Kingdom - epidemiology
Vaccination
Vaccination - methods
Vaccines
Virus diseases
Viruses
Quelle: Alma/SFX Local Collection
Publisher: Netherlands: Elsevier Ltd
ID: ISSN: 0264-410X
Link: https://www.ncbi.nlm.nih.gov/pubmed/29941327
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_2059563750
title: Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy
format: Article
creator:
  • Scheltema, Nienke M
  • Kavelaars, Xynthia M
  • Thorburn, Kentigern
  • Hennus, Marije P
  • van Woensel, Job B
  • van der Ent, Cornelis K
  • Borghans, José A.M
  • Bont, Louis J
  • Drylewicz, Julia
subjects:
  • Analysis
  • Antibodies, Viral - blood
  • Antibody Formation
  • Children
  • Development and progression
  • Female
  • Gestational age
  • Hospitalization
  • Humans
  • Immunization
  • Infant
  • Infant mortality
  • Infant, Newborn
  • Infants
  • Infections
  • Life-threatening infections
  • Male
  • Maternal vaccination
  • Mathematical model
  • Mathematical models
  • Medical research
  • Medicine, Experimental
  • Models
  • Models, Theoretical
  • Mortality
  • Netherlands - epidemiology
  • Patient outcomes
  • Pregnancy
  • Respiratory syncytial virus
  • Respiratory Syncytial Virus Infections - epidemiology
  • Respiratory Syncytial Virus Infections - mortality
  • Respiratory Syncytial Virus Infections - prevention & control
  • Respiratory Syncytial Virus Vaccines - administration & dosage
  • Respiratory Syncytial Virus Vaccines - immunology
  • RSV
  • Survival Analysis
  • United Kingdom - epidemiology
  • Vaccination
  • Vaccination - methods
  • Vaccines
  • Virus diseases
  • Viruses
ispartof: Vaccine, 2018-07-25, Vol.36 (31), p.4693-4700
description: Respiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here, we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection in infants. We developed a mathematical model for maternal vaccine-induced antibody dynamics and used characteristics of a maternal RSV vaccine currently in phase 3 of clinical development. The model was applied to data from two cohorts of children younger than 12 months with RSV-related paediatric intensive care unit (PICU) admission in the United Kingdom (n = 370) and the Netherlands (n = 167), and a cohort of 211 children younger than 12 months with RSV-related in-hospital death from 20 countries worldwide. Our model predicted that, depending on vaccine efficiency, maternal vaccination at 30 weeks’ gestational age could have prevented 62–75% of RSV-related PICU admissions in the United Kingdom and 76–87% in the Netherlands. For the global mortality cohort, the model predicted that maternal vaccination could have prevented 29–48% of RSV-related in-hospital deaths. Preterm children and children with comorbidities were predicted to benefit less than (healthy) term children. Maternal vaccination against RSV may substantially decrease life-threatening RSV infections in infants.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0264-410X
fulltext: fulltext
issn:
  • 0264-410X
  • 1873-2518
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.5920897
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_2059563750
sourceformatXML
sourcesystemPC
galeidA545392623
sourcerecordidA545392623
originalsourceidFETCH-LOGICAL-1516t-3612e06c47ab0539886949a219b65e0cdb02cd2250be46d52b451523f461ce5d3
addsrcrecordideNqFkU1v1DAQhiMEoqXwE0CRuHBJ8HeSE6qq8iFVggNInLAce1K8Suytnay0_57JZumBC7Il2-PnnRn7LYrXlNSUUPV-Vx-MtT5AzQhta6JqwuiT4pK2Da-YpO3T4pIwJSpByc-L4kXOO0KI5LR7XlywrhOUs-ayePgWZwizN2Ppp72xcxmHcjIzpIChrYSZfQwlztEPUM2_E-B98OG-TJD3Ppk5pmOZj8EeT4kOPi259GEAe1K6Ja0wBgwiL4tngxkzvDqvV8WPj7ffbz5Xd18_fbm5vquopGquuKIMiLKiMT223bWt6kRnGO16JYFY1xNmHWOS9CCUk6wXkkrGB6GoBen4VfFuy7tP8WGBPOvJZwvjaALEJWtGZCcVbyRB9O0_6C4u6weslOKqwfICqXqj7s0IGl8T52QsDgeTtzHA4DF-LQV2yxTjKJCbwKaYc4JB75OfTDpqSvRqot7ps4l6NVETpdFE1L05t7P0E7hH1V_XEPi1AcEk6_MjYCaLEh2N1_slwXrWYcR9P3p7cjFrCZy3FISW3DVauHbQnWNEG2IUdNANtm-xwIetAKBBBw9JZ-shWHA-oanaRf-fN_wBMmPSeQ
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid2063673984
display
typearticle
titlePotential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy
sourceAlma/SFX Local Collection
creatorScheltema, Nienke M ; Kavelaars, Xynthia M ; Thorburn, Kentigern ; Hennus, Marije P ; van Woensel, Job B ; van der Ent, Cornelis K ; Borghans, José A.M ; Bont, Louis J ; Drylewicz, Julia
creatorcontribScheltema, Nienke M ; Kavelaars, Xynthia M ; Thorburn, Kentigern ; Hennus, Marije P ; van Woensel, Job B ; van der Ent, Cornelis K ; Borghans, José A.M ; Bont, Louis J ; Drylewicz, Julia
descriptionRespiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here, we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection in infants. We developed a mathematical model for maternal vaccine-induced antibody dynamics and used characteristics of a maternal RSV vaccine currently in phase 3 of clinical development. The model was applied to data from two cohorts of children younger than 12 months with RSV-related paediatric intensive care unit (PICU) admission in the United Kingdom (n = 370) and the Netherlands (n = 167), and a cohort of 211 children younger than 12 months with RSV-related in-hospital death from 20 countries worldwide. Our model predicted that, depending on vaccine efficiency, maternal vaccination at 30 weeks’ gestational age could have prevented 62–75% of RSV-related PICU admissions in the United Kingdom and 76–87% in the Netherlands. For the global mortality cohort, the model predicted that maternal vaccination could have prevented 29–48% of RSV-related in-hospital deaths. Preterm children and children with comorbidities were predicted to benefit less than (healthy) term children. Maternal vaccination against RSV may substantially decrease life-threatening RSV infections in infants.
identifier
0ISSN: 0264-410X
1EISSN: 1873-2518
2DOI: 10.1016/j.vaccine.2018.06.021
3PMID: 29941327
languageeng
publisherNetherlands: Elsevier Ltd
subjectAnalysis ; Antibodies, Viral - blood ; Antibody Formation ; Children ; Development and progression ; Female ; Gestational age ; Hospitalization ; Humans ; Immunization ; Infant ; Infant mortality ; Infant, Newborn ; Infants ; Infections ; Life-threatening infections ; Male ; Maternal vaccination ; Mathematical model ; Mathematical models ; Medical research ; Medicine, Experimental ; Models ; Models, Theoretical ; Mortality ; Netherlands - epidemiology ; Patient outcomes ; Pregnancy ; Respiratory syncytial virus ; Respiratory Syncytial Virus Infections - epidemiology ; Respiratory Syncytial Virus Infections - mortality ; Respiratory Syncytial Virus Infections - prevention & control ; Respiratory Syncytial Virus Vaccines - administration & dosage ; Respiratory Syncytial Virus Vaccines - immunology ; RSV ; Survival Analysis ; United Kingdom - epidemiology ; Vaccination ; Vaccination - methods ; Vaccines ; Virus diseases ; Viruses
ispartofVaccine, 2018-07-25, Vol.36 (31), p.4693-4700
rights
02018 The Author(s)
1info:eu-repo/semantics/openAccess
2Copyright © 2018 The Author(s). Published by Elsevier Ltd.. All rights reserved.
3COPYRIGHT 2018 Elsevier B.V.
42018. The Author(s)
lds50peer_reviewed
oafree_for_read
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29941327$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Scheltema, Nienke M
1Kavelaars, Xynthia M
2Thorburn, Kentigern
3Hennus, Marije P
4van Woensel, Job B
5van der Ent, Cornelis K
6Borghans, José A.M
7Bont, Louis J
8Drylewicz, Julia
title
0Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy
1Vaccine
addtitleVaccine
descriptionRespiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here, we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection in infants. We developed a mathematical model for maternal vaccine-induced antibody dynamics and used characteristics of a maternal RSV vaccine currently in phase 3 of clinical development. The model was applied to data from two cohorts of children younger than 12 months with RSV-related paediatric intensive care unit (PICU) admission in the United Kingdom (n = 370) and the Netherlands (n = 167), and a cohort of 211 children younger than 12 months with RSV-related in-hospital death from 20 countries worldwide. Our model predicted that, depending on vaccine efficiency, maternal vaccination at 30 weeks’ gestational age could have prevented 62–75% of RSV-related PICU admissions in the United Kingdom and 76–87% in the Netherlands. For the global mortality cohort, the model predicted that maternal vaccination could have prevented 29–48% of RSV-related in-hospital deaths. Preterm children and children with comorbidities were predicted to benefit less than (healthy) term children. Maternal vaccination against RSV may substantially decrease life-threatening RSV infections in infants.
subject
0Analysis
1Antibodies, Viral - blood
2Antibody Formation
3Children
4Development and progression
5Female
6Gestational age
7Hospitalization
8Humans
9Immunization
10Infant
11Infant mortality
12Infant, Newborn
13Infants
14Infections
15Life-threatening infections
16Male
17Maternal vaccination
18Mathematical model
19Mathematical models
20Medical research
21Medicine, Experimental
22Models
23Models, Theoretical
24Mortality
25Netherlands - epidemiology
26Patient outcomes
27Pregnancy
28Respiratory syncytial virus
29Respiratory Syncytial Virus Infections - epidemiology
30Respiratory Syncytial Virus Infections - mortality
31Respiratory Syncytial Virus Infections - prevention & control
32Respiratory Syncytial Virus Vaccines - administration & dosage
33Respiratory Syncytial Virus Vaccines - immunology
34RSV
35Survival Analysis
36United Kingdom - epidemiology
37Vaccination
38Vaccination - methods
39Vaccines
40Virus diseases
41Viruses
issn
00264-410X
11873-2518
fulltexttrue
rsrctypearticle
creationdate2018
recordtypearticle
recordideNqFkU1v1DAQhiMEoqXwE0CRuHBJ8HeSE6qq8iFVggNInLAce1K8Suytnay0_57JZumBC7Il2-PnnRn7LYrXlNSUUPV-Vx-MtT5AzQhta6JqwuiT4pK2Da-YpO3T4pIwJSpByc-L4kXOO0KI5LR7XlywrhOUs-ayePgWZwizN2Ppp72xcxmHcjIzpIChrYSZfQwlztEPUM2_E-B98OG-TJD3Ppk5pmOZj8EeT4kOPi259GEAe1K6Ja0wBgwiL4tngxkzvDqvV8WPj7ffbz5Xd18_fbm5vquopGquuKIMiLKiMT223bWt6kRnGO16JYFY1xNmHWOS9CCUk6wXkkrGB6GoBen4VfFuy7tP8WGBPOvJZwvjaALEJWtGZCcVbyRB9O0_6C4u6weslOKqwfICqXqj7s0IGl8T52QsDgeTtzHA4DF-LQV2yxTjKJCbwKaYc4JB75OfTDpqSvRqot7ps4l6NVETpdFE1L05t7P0E7hH1V_XEPi1AcEk6_MjYCaLEh2N1_slwXrWYcR9P3p7cjFrCZy3FISW3DVauHbQnWNEG2IUdNANtm-xwIetAKBBBw9JZ-shWHA-oanaRf-fN_wBMmPSeQ
startdate20180725
enddate20180725
creator
0Scheltema, Nienke M
1Kavelaars, Xynthia M
2Thorburn, Kentigern
3Hennus, Marije P
4van Woensel, Job B
5van der Ent, Cornelis K
6Borghans, José A.M
7Bont, Louis J
8Drylewicz, Julia
general
0Elsevier Ltd
1Elsevier B.V
2Elsevier Limited
scope
06I.
1AAFTH
25DI
35DJ
4AGBBJ
5QVL
6CGR
7CUY
8CVF
9ECM
10EIF
11NPM
12AAYXX
13CITATION
14BSHEE
153V.
167QL
177RV
187T2
197T5
207U9
217X7
227XB
2388C
2488E
258AO
268C1
278FE
288FH
298FI
308FJ
318FK
328G5
33ABUWG
34AZQEC
35BBNVY
36BENPR
37BHPHI
38C1K
39DWQXO
40FYUFA
41GHDGH
42GNUQQ
43GUQSH
44H94
45HCIFZ
46K9-
47K9.
48KB0
49LK8
50M0R
51M0S
52M0T
53M1P
54M2O
55M7N
56M7P
57MBDVC
58NAPCQ
59PQEST
60PQQKQ
61PQUKI
62Q9U
637X8
sort
creationdate20180725
titlePotential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy
authorScheltema, Nienke M ; Kavelaars, Xynthia M ; Thorburn, Kentigern ; Hennus, Marije P ; van Woensel, Job B ; van der Ent, Cornelis K ; Borghans, José A.M ; Bont, Louis J ; Drylewicz, Julia
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1516t-3612e06c47ab0539886949a219b65e0cdb02cd2250be46d52b451523f461ce5d3
rsrctypearticles
prefilterarticles
languageeng
creationdate2018
topic
0Analysis
1Antibodies, Viral - blood
2Antibody Formation
3Children
4Development and progression
5Female
6Gestational age
7Hospitalization
8Humans
9Immunization
10Infant
11Infant mortality
12Infant, Newborn
13Infants
14Infections
15Life-threatening infections
16Male
17Maternal vaccination
18Mathematical model
19Mathematical models
20Medical research
21Medicine, Experimental
22Models
23Models, Theoretical
24Mortality
25Netherlands - epidemiology
26Patient outcomes
27Pregnancy
28Respiratory syncytial virus
29Respiratory Syncytial Virus Infections - epidemiology
30Respiratory Syncytial Virus Infections - mortality
31Respiratory Syncytial Virus Infections - prevention & control
32Respiratory Syncytial Virus Vaccines - administration & dosage
33Respiratory Syncytial Virus Vaccines - immunology
34RSV
35Survival Analysis
36United Kingdom - epidemiology
37Vaccination
38Vaccination - methods
39Vaccines
40Virus diseases
41Viruses
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Scheltema, Nienke M
1Kavelaars, Xynthia M
2Thorburn, Kentigern
3Hennus, Marije P
4van Woensel, Job B
5van der Ent, Cornelis K
6Borghans, José A.M
7Bont, Louis J
8Drylewicz, Julia
collection
0ScienceDirect Open Access Titles
1Elsevier:ScienceDirect:Open Access
2NARCIS
3NARCIS: Datasets
4Narcis: Open Access
5NARCIS:Publications
6Medline
7MEDLINE
8MEDLINE (Ovid)
9MEDLINE
10MEDLINE
11PubMed
12CrossRef
13Academic OneFile (A&I only)
14ProQuest Central (Corporate)
15Bacteriology Abstracts (Microbiology B)
16Nursing & Allied Health Database
17Health and Safety Science Abstracts (Full archive)
18Immunology Abstracts
19Virology and AIDS Abstracts
20Health & Medical Collection
21ProQuest Central (purchase pre-March 2016)
22Healthcare Administration Database (Alumni)
23Medical Database (Alumni Edition)
24ProQuest Pharma Collection
25Public Health Database
26ProQuest SciTech Collection
27ProQuest Natural Science Collection
28Hospital Premium Collection
29Hospital Premium Collection (Alumni Edition)
30ProQuest Central (Alumni) (purchase pre-March 2016)
31Research Library (Alumni Edition)
32ProQuest Central (Alumni Edition)
33ProQuest Central Essentials
34Biological Science Collection
35ProQuest Central
36Natural Science Collection
37Environmental Sciences and Pollution Management
38ProQuest Central Korea
39Health Research Premium Collection
40Health Research Premium Collection (Alumni)
41ProQuest Central Student
42Research Library Prep
43AIDS and Cancer Research Abstracts
44SciTech Premium Collection
45Consumer Health Database (Alumni Edition)
46ProQuest Health & Medical Complete (Alumni)
47Nursing & Allied Health Database (Alumni Edition)
48ProQuest Biological Science Collection
49Consumer Health Database
50Health & Medical Collection (Alumni Edition)
51Healthcare Administration Database
52Medical Database
53Research Library
54Algology Mycology and Protozoology Abstracts (Microbiology C)
55Biological Science Database
56Research Library (Corporate)
57Nursing & Allied Health Premium
58ProQuest One Academic Eastern Edition
59ProQuest One Academic
60ProQuest One Academic UKI Edition
61ProQuest Central Basic
62MEDLINE - Academic
jtitleVaccine
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Scheltema, Nienke M
1Kavelaars, Xynthia M
2Thorburn, Kentigern
3Hennus, Marije P
4van Woensel, Job B
5van der Ent, Cornelis K
6Borghans, José A.M
7Bont, Louis J
8Drylewicz, Julia
formatjournal
genrearticle
ristypeJOUR
atitlePotential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy
jtitleVaccine
addtitleVaccine
date2018-07-25
risdate2018
volume36
issue31
spage4693
epage4700
pages4693-4700
issn0264-410X
eissn1873-2518
abstractRespiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here, we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection in infants. We developed a mathematical model for maternal vaccine-induced antibody dynamics and used characteristics of a maternal RSV vaccine currently in phase 3 of clinical development. The model was applied to data from two cohorts of children younger than 12 months with RSV-related paediatric intensive care unit (PICU) admission in the United Kingdom (n = 370) and the Netherlands (n = 167), and a cohort of 211 children younger than 12 months with RSV-related in-hospital death from 20 countries worldwide. Our model predicted that, depending on vaccine efficiency, maternal vaccination at 30 weeks’ gestational age could have prevented 62–75% of RSV-related PICU admissions in the United Kingdom and 76–87% in the Netherlands. For the global mortality cohort, the model predicted that maternal vaccination could have prevented 29–48% of RSV-related in-hospital deaths. Preterm children and children with comorbidities were predicted to benefit less than (healthy) term children. Maternal vaccination against RSV may substantially decrease life-threatening RSV infections in infants.
copNetherlands
pubElsevier Ltd
pmid29941327
doi10.1016/j.vaccine.2018.06.021
oafree_for_read